anti-Solute Carrier Family 5 (Iodide Transporter), Member 8 (SLC5A8) Antikörper

Mouse (Murine) Solute Carrier Family 5 (Iodide Transporter), Member 8 (SLC5A8) Interaktionspartner

1. Slc5a8 is an obligatory link between dietary fibre and mucosal immune system via the bacterial metabolite butyrate and that this transporter is a conditional tumour suppressor in colon linked to dietary fibre content.

2. Data indicate oncogenic HRAS (HRAS(G12V)) as a potent mediator of SLC5A8 silencing in human nontransformed normal mammary epithelial cell lines and in mouse mammary tumors through DNMT1.

3. Efficacy of LP or their secreted soluble factors to stimulate SMCT1 expression and function and to counteract the inhibitory effects of TNF-alpha on butyrate absorption could have potential therapeutic value.

4. butyrate and propionate block the generation of dendritic cells from bone marrow stem cells, since Slc5a8 transports butyrate and propionate into cells, and these two bacterial metabolites inhibit histone deacetylases

5. Sodium-coupled electrogenic transport of pyroglutamate (5-oxoproline) via SLC5A8, a monocarboxylate transporter.

6. In conventional mice with normal bacterial colonization of the intestinal tract, GPR109A and SLC5A8 are expressed on the apical membrane of epithelial cells lining the ileum and colon.

7. CDX1 and CDX2 bind the promoter region of SLC5A8 and up-regulate its expression in cultured cells and in colonic epithelium.

8. slc5a8 is expressed abundantly in the kidney and plays a role in the active reabsorption of lactate

9. SMCT functions not only as a Na+-coupled transporter for short-chain fatty acids and lactate but also as a Na+-coupled transporter for the water-soluble vitamin nicotinic acid.

10. The shared epigenetic inactivation of mSLC5A8 in mouse gliomas indicates an additional degree of commonality in the origin and/or pathway to tumorigenesis between primary human tumors and these mouse models of gliomas.

11. Data describe the cellular localization of Slc5a8 in the murine gastrointestinal tract and kidney by in situ hybridization and immunohistochemistry.

12. slc5a8 and slc5a12 in kidney in c/ebpdelta-/- mice have a role in the renal handling of lactate and urate

13. SMCT1(SLC5A8) expression in intestinal tract was examined by immunofluorescence microscopy.

14. These data provide the first evidence for the expression of SMCT1 and SMCT2 in the retina and for the cell-type specific distribution of these transporters within the retina.

15. low-affinity transporter SMCT2 initiates lactate absorption in the early parts of the proximal tubule followed by the participation of the high-affinity transporter SMCT1 in the latter parts of the proximal tubule.

16. Cellular expression of a sodium-dependent monocarboxylate transporter (Slc5a8) and the MCT1/2 in the mouse kidney.

Human Solute Carrier Family 5 (Iodide Transporter), Member 8 (SLC5A8) Interaktionspartner

1. SLC5A8 expression is repressed in human cervical cancer (CC) tumors and cell lines through epigenetic silencing.

2. Results indicate that the SMCT1-PDZK1 interaction thus plays an important role in both lactate handling as well as urate reabsorption in the human kidney.

3. Pendrin residues which are mutated in Pendred's syndrome are identical to those in the aligned position of sodium/iodide symporter (NIS) and apical iodide transporter (AIT).

4. The present work reveals much lower iodide affinity in the pocket of human SMCT1 analogous to the putative iodide-binding pocket of human NIS.

5. Human SMCT1 is regulated by insulin and SGK1.

6. Data suggest positive correlation between BMI (body mass index)/waist circumference in morbidly obese or obese subjects and jejunal mucosa mRNA abundance of SMCT1; BMI was not significantly correlated with mRNA abundance for glucose transporters SGLT1 and GLUT2 or the low-affinity short-chain fatty acid/monocarboxylate transporter SMCT2.

7. Underexpression of SLC5A8 is associated with hepatocellular carcinoma.

8. Data suggest that SLC5A8, SLC5A5 (sodium-iodide symporter), and SLC26A4 (pendrin), the 3 known iodide transporters, are important in breast tissue metabolism in lactation and in breast neoplasms. [REVIEW]

9. Gene silencing of SLC5A8 by hypermethylation was associated with poor prognosis in cases of node-negative stage I and II lung adenocarcinoma.

10. Data indicate oncogenic HRAS (HRAS(G12V)) as a potent mediator of SLC5A8 silencing in human nontransformed normal mammary epithelial cell lines and in mouse mammary tumors through DNMT1.

11. These results suggest that DNA methylation in the SLC5A8 promoter region may suppress the expression of SLC5A8 in lung tumor.

12. SLC5A8 suppresses tumour progression through depletion of survivin without involving its transport function

13. SLC5A8 nuclear translocation and loss of expression are associated with poor outcome in pancreatic ductal adenocarcinoma.

14. SLC5A8 has a role in prostate cancer risk and aggressiveness

15. SLC5A8 is highly methylated in African American colon adenomas

16. Efficacy of LP or their secreted soluble factors to stimulate SMCT1 expression and function and to counteract the inhibitory effects of TNF-alpha on butyrate absorption could have potential therapeutic value.

17. Sodium-coupled electrogenic transport of pyroglutamate (5-oxoproline) via SLC5A8, a monocarboxylate transporter.

18. Results verify IRX1, EBF3, SLC5A8, SEPT9, and FUSSEL18 as valid methylation markers in two separate sets of HNSCC specimens; also preliminarily show a trend between HPV16 positivity and target gene hypermethylation of IRX1, EBF3, SLC5A8, and SEPT9.

19. results elucidate the mechanism underlying the regulation of SLC5A8 gene transcription and also define a novel regulatory sequence that may be used to increase expression of the SLC5A8 gene in cancer gene therapy

20. SMCT1 possesses a anionic leak current that becomes significant whenever external Na(+) concentration is reduced